Related Experiment Videos
Short-term etretinate therapy for prurigo chronica multiformis
Kimio Fujii1, Yuko Kanno, Kenji Konishi
1Department of Dermatology Kobe City General Hospital, Kobe, Japan.
The Journal of Dermatology
|May 7, 2002
Summary
Etretinate therapy offers a safe and effective treatment for prurigo chronica multiformis, a chronic skin condition. Moderate doses of etretinate, combined with other treatments, helped patients achieve remission, even when conventional therapies failed.
Area of Science:
- Dermatology
- Pharmacology
Background:
- Prurigo chronica multiformis is a chronic, intensely itchy skin disorder with unknown causes.
- Current treatments, including topical steroids and antihistamines, often lack effectiveness.
Purpose of the Study:
- To evaluate the efficacy and safety of etretinate therapy for prurigo chronica multiformis.
Main Methods:
- Thirty-seven patients with prurigo chronica multiformis received 30 mg/day etretinate, topical steroids, and oral antihistamines.
- Etretinate was stopped upon remission and patients were followed for at least four weeks.
- Recurrence was treated with re-administration of etretinate.
Main Results:
- Within four weeks, 18 patients achieved total remission and 14 achieved partial remission.
- Overall, 27 patients achieved remission with an average treatment duration of 4.4 weeks.
- Recurrence occurred in 23 of 27 patients, but re-treatment with etretinate was effective.
Conclusions:
- Moderate-dose etretinate is a safe and effective treatment for prurigo chronica multiformis.
- Etretinate shows promise for managing this condition, especially when resistant to conventional therapies.
- Further research may explore optimal dosing and long-term management strategies.